Transplant Surgery Research
Kling, C., Perkins, J., Reyes, J., & Montenovo, M. (2018). Living Donation Versus Donation After Circulatory Death Liver Transplantation for Low MELD Recipients. Liver Transplantation: Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 10 April 2018.
Metcalf, R., Pagano, M., Hess, J., Reyes, J., Perkins, J., & Montenovo, M. (2018). A data‐driven patient blood management strategy in liver transplantation. Vox Sanguinis, 113(5), 421-429.
Shingina, A., & Montenovo, M. (2018). Go/No‐Go decision in donor liver utilization: The value of preretrieval liver biopsy. Liver Transplantation, 24(2), 159-160.
Sibulesky, L., Kling, C., Blosser, C., Johnson, C., Limaye, A., Bakthavatsalam, R., . . . Perkins, J. (2018). Are we underestimating the quality of aviremic hepatitis C-positive kidneys? Time to reconsider. American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons, American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 16 February 2018.
Montenovo, M. I., Rahnemai-Azar, A., Reyes, J., & Perkins, J. (2018). Clinical impact and risk factors of portal vein thrombosis for patients on wait list for liver transplant. Experimental and Clinical Transplantation, 16(2), 166-171.
Rahnemai-Azar, A., Perkins, J., Leca, N., Blosser, C., Johnson, C., Morrison, S., . . . Sibulesky, L. (2018). Unintended Consequences in Use of Increased Risk Donor Kidneys in the New Kidney Allocation Era. Transplantation Proceedings, 50(1), 14-19.
Vitin, A., Pennington, M., Bowdle, T., Rayhill, S., Sibulesky, L., Reyes, J., & Mccabe, J. (2018). Stress (Takotsubo) Cardiomyopathy During Liver Transplantation: Case Study and Literature Review. Transplantation Proceedings, 50(1), 211-216.
Reyes, J. (2017). Determinants of Failure in Hepatic Transplant. JAMA Surgery,153(5), 444-445.
Jalikis, F., Hoch, B., Bakthavatsalam, R., & Montenovo, M. (2017). Sporadic Retroperitoneal Hemangioblastoma: Report of a Case and Review of the Literature. Case Reports in Pathology, 2017, 5.
Reyes J, Jalikis, Olson, Yeh, & Montenovo M. (2017). Use of NanoICE for Procurement Achieves Better Cooling of Liver Grafts. Transplantation Proceedings, 49(6), 1449-1454.
Montenovo, M., Javed, E., Bakthavatsalam, R., & Reyes, J. (2017). Splenic Subcapsular Hematoma After Endoscopic Retrograde Cholangiopancreatography in a Liver Transplant Recipient: Case Report and Literature Review. Experimental And Clinical Transplantation, 15(1), 103-105.
Rahnemai-Azar A, Penna M, Morrison, Rayhill S, Sibulesky L, Muczynski, & Bakthavatsalam R. (2017). Coloduodenovesical Fistula After Simultaneous Pancreas-Kidney Transplant: Case Report and Review of the Literature. Transplantation Proceedings, 49(8), 1960-1962.
Kling, C. E., Perkins, J. D., Carithers, R. L., Sibulesky, L., & Donovan, D. (2017). Recent trends in liver transplantation for alcoholic liver disease in the United States. World Journal of Hepatology, 9(36), 1315-1321.
Sibulesky, L., Kling, C., Limaye, A., & Johnson, C. (2017). Is Kidney Donor Profile Index (KDPI) Valid for Hepatitis C Aviremic Kidneys? Annals of Transplantation, 22, 663-664.
Kling, C., Perkins, J., Landis, C., Limaye, A., & Sibulesky, L. (2017). Utilization of Organs From Donors According to Hepatitis C Antibody and Nucleic Acid Testing Status: Time for Change. American Journal of Transplantation, 17(11), 2863-2868.
Stephen C. Rayhill, MD— “A 24-month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs. mycophenolate with standard calicnerurin inhibitor in de novo renal transplantation—Advancing renal TRANSplant eFficacy and safety Outcomes with an eveRolimus-based regiMen (TRANSFORM).” Novartis Pharmaceutical Corporation. Co-investigator IRB #47855 Trial Protocol CRAD001A244. 8/6/14-12/31/2018, $226,674
“A Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of QPI-1002 for Prevention of Delayed Graft Function in Recipients of a Donation After Brain Death Older Donor Kidney Transplant (ReGIFT).” Quark Pharmaceuticals, Inc. 2016- present
James D. Perkins, MD and Jorge D. Reyes, MD— “Genomic Analysis of Hepatoblastoma in Children: Pilot study to identify specific genes indicating recurrence after treatment for hepatoblastoma for future longitudinal studies.” Gerber Foundation. 12/2/2013-11/30/16 $144,839
James D. Perkins, MD Professor Clinical outcomes research examines speciﬁc illnesses and therapies and evaluates whether current practices are truly effective. Questions are asked about such factors as medication dosages, operative techniques, information management, and infection control. Based on the results of these studies, protocols may be adjusted to give improved results. Improved results in the ﬁeld of transplantation might take the form of higher patient survival rates, lower rejection rates concomitant with low infection rates, more effective use of immuosuppressive therapy, or shorter hospital stay. Complete Research Report >>
Jorge D. Reyes, MD Professor and Chief New immunosuppressive drugs improve the short-term survival of organ transplant recipients. However, long-term survival remains comparatively poor. This is likely due to the fact that immunosuppressive strategies are not tolerogenic. Transplant tolerance is likely to arise not from improved immunosuppressive regimens, but from improved understanding of the normal mechanisms that generate and maintain self-tolerance, and the ability to manipulate these mechanisms for the prevention and treatment of transplant rejection. Complete Research Report >>